Vanguard Group Inc. Increases Stock Position in Replimune Group, Inc. $REPL

Key Points

• Vanguard Group Inc. increased its holdings in Replimune Group by 6.6% during Q1, owning 3,833,033 shares valued at $37.37 million.
• Replimune Group's recent quarterly earnings report revealed a loss of ($0.95) per share, missing expectations of ($0.83) by $0.12.
• Analysts have downgraded their price targets for Replimune Group, with JPMorgan now setting a target at $9.00, down from $19.00.

Vanguard Group Inc. increased its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 6.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,833,033 shares of the company's stock after buying an additional 237,185 shares during the period. Vanguard Group Inc. owned 4.98% of Replimune Group worth $37,372,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. US Bancorp DE boosted its holdings in Replimune Group by 582.6% during the first quarter. US Bancorp DE now owns 4,594 shares of the company's stock worth $45,000 after buying an additional 3,921 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Replimune Group by 106.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company's stock worth $111,000 after buying an additional 5,876 shares in the last quarter. Victory Capital Management Inc. raised its position in Replimune Group by 67.4% during the first quarter. Victory Capital Management Inc. now owns 75,140 shares of the company's stock worth $733,000 after acquiring an additional 30,260 shares during the period. Arizona State Retirement System lifted its holdings in Replimune Group by 19.7% during the first quarter. Arizona State Retirement System now owns 15,439 shares of the company's stock valued at $151,000 after purchasing an additional 2,545 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Replimune Group by 8.4% during the first quarter. Bank of New York Mellon Corp now owns 189,177 shares of the company's stock valued at $1,844,000 after purchasing an additional 14,659 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Stock Performance

NASDAQ:REPL opened at $5.68 on Wednesday. The company's 50-day moving average price is $7.62 and its 200-day moving average price is $9.16. The company has a current ratio of 6.94, a quick ratio of 6.94 and a debt-to-equity ratio of 0.21. The company has a market cap of $443.38 million, a P/E ratio of -1.75 and a beta of 0.67. Replimune Group, Inc. has a twelve month low of $2.68 and a twelve month high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). On average, sell-side analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Replimune Group news, CFO Emily Luisa Hill sold 9,154 shares of Replimune Group stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $5.37, for a total transaction of $49,156.98. Following the transaction, the chief financial officer directly owned 134,368 shares of the company's stock, valued at $721,556.16. The trade was a 6.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 5.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $9.00 price objective (down from $19.00) on shares of Replimune Group in a report on Tuesday, July 22nd. Leerink Partners reaffirmed a "market perform" rating and set a $3.00 price objective (down from $21.00) on shares of Replimune Group in a report on Tuesday, July 22nd. Wedbush reaffirmed a "neutral" rating and set a $4.00 price objective (down from $19.00) on shares of Replimune Group in a report on Tuesday, July 22nd. Jefferies Financial Group decreased their price objective on shares of Replimune Group from $31.00 to $6.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Finally, Leerink Partnrs downgraded shares of Replimune Group from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 22nd. Two research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $6.50.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.